Clarus Therapeutics Holdings, Inc.
OTC: CRXTQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert E. Dudley
- Employees
- 16
- Headquarters
- Northbrook, United States
- IPO year
- 2021
- Market cap
- $72.8K
- Website
- https://clarustherapeutics.com
Loading CRXTQ…
Loading profile data…Frequently asked questions about CRXTQ
What does Clarus Therapeutics Holdings, Inc. (CRXTQ) do?
Clarus Therapeutics Holdings, Inc. is a pharmaceutical enterprise dedicated to developing and marketing oral testosterone replacement therapies across the United States. Its primary offering is JATENZO, an oral soft gel formulation of testosterone undecanoate, prescribed for men suffering from hypogonadism. The company has also entered into lice...
Where does CRXTQ trade?
Clarus Therapeutics Holdings, Inc. (CRXTQ) trades on the Other OTC.
What sector is CRXTQ in?
Clarus Therapeutics Holdings, Inc. (CRXTQ) operates in the Healthcare sector, specifically in the Drug Manufacturers - General industry.
Who is the CEO of Clarus Therapeutics Holdings, Inc.?
Robert E. Dudley is the chief executive officer of Clarus Therapeutics Holdings, Inc. (CRXTQ).
Where is Clarus Therapeutics Holdings, Inc. headquartered?
Clarus Therapeutics Holdings, Inc. is headquartered in United States.
Does CRXTQ pay a dividend?
Clarus Therapeutics Holdings, Inc. (CRXTQ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CRXTQ go public?
Clarus Therapeutics Holdings, Inc. (CRXTQ) completed its initial public offering in 2021.